. "I" . "16" . . . "Expression of SHB in prostate cancer tissue: its role in the diagnostics and prognostics"@en . . "http://www.czechurol.cz/dwnld/cu_12_01_58_66.pdf" . . . "Stanoven\u00ED exprese SHB v tk\u00E1ni karcinomu prostaty: vyu\u017Eit\u00ED v diagnostice a prognostice"@cs . "RIV/00064203:_____/12:8550!RIV13-MZ0-00064203" . "Jarol\u00EDm, Ladislav" . "Vesel\u00FD, \u0160t\u011Bp\u00E1n" . . "Stanoven\u00ED exprese SHB v tk\u00E1ni karcinomu prostaty: vyu\u017Eit\u00ED v diagnostice a prognostice"@cs . "6"^^ . "Stanoven\u00ED exprese SHB v tk\u00E1ni karcinomu prostaty: vyu\u017Eit\u00ED v diagnostice a prognostice" . . . "C\u00EDl: Karcinom prostaty je nej\u010Dast\u011Bj\u0161\u00ED urologickou onkologickou p\u0159\u00ED\u010Dinou \u00FAmrt\u00ED. Etiologie onemocn\u011Bn\u00ED z\u016Fst\u00E1v\u00E1 nezn\u00E1m\u00E1. Byla identifikov\u00E1na \u0159ada gen\u016F n\u00E1chylnosti ke karcinomu prostaty, u kter\u00FDch byla prok\u00E1z\u00E1na asociace zm\u011Bny genov\u00E9 exprese s v\u00FDskytem karcinomu. Adaptorov\u00FD protein SHB je sou\u010D\u00E1st\u00ED syst\u00E9mu regulace apopt\u00F3zy angiogeneze a bun\u011B\u010Dn\u00E9ho cyklu. P\u0159i jeho zv\u00FD\u0161en\u00E9 expresi byla prok\u00E1z\u00E1na sn\u00ED\u017Een\u00E1 proliferace prostatick\u00FDch n\u00E1dorov\u00FDch bun\u011Bk PC3. C\u00EDlem prezentovan\u00E9 pr\u00E1ce je stanoven\u00ED genov\u00E9 exprese SHB v tk\u00E1ni karcinomu prostaty, jej\u00ED porovn\u00E1n\u00ED s expres\u00ED v tk\u00E1ni benign\u00ED hyperplazie a vyhodnoceni diagnostick\u00E9ho a prognostick\u00E9ho potenci\u00E1lu SHB. Metody: V letech 2008-2010 byla provedena izolace mRNA z tk\u00E1n\u011B karcinomu prostaty u 53 pacient\u016F. Jako kontroln\u00ED skupina byla pou\u017Eita tk\u00E1\u0148 prostaty u 24 pacient\u016F s benign\u00ED hyperplazi\u00ED. Izolace mRNA byla prov\u00E1d\u011Bna u v\u0161ech pacient\u016F identick\u00FDm zp\u016Fsobem pomoc\u00ED soupravy Oligotex Direct mRNA Midi/Maxi. Po RT-PCR byla exprese vybran\u00E9ho vzorku vizualizov\u00E1na pomoc\u00ED elektrofor\u00E9zy Optick\u00E1 hustota byla m\u011B\u0159ena denzitometricky Pro v\u00FDpo\u010Det relativn\u00ED exprese genu byl zvolen provozn\u00ED gen GAD k\u00F3duj\u00EDc\u00ED glyceraldehyd-3-fosf\u00E1tdehydrogen\u00E1zu. Dosa\u017Een\u00E9 v\u00FDsledky byly statisticky vyhodnoceny. V\u00FDsledky: Z\u00EDskan\u00E1 data prok\u00E1zala ni\u017E\u0161\u00ED relativn\u00ED expresi SHB v tk\u00E1n\u00ED karcinomu (p < 0, 001). P\u0159i rozd\u011Blen\u00ED karcinomu na lokalizovan\u00E9 (T2) a lok\u00E1ln\u011B pokro\u010Dil\u00E9 (T3-T4) byl pozorov\u00E1n trend k ni\u017E\u0161\u00ED expresi u lok\u00E1ln\u011B pokro \u010Dil\u00FDch forem, kter\u00FD ale nedos\u00E1hl statistick\u00E9 v\u00FDznamnosti (p < 0,0693). P\u0159i porovn\u00E1n\u00ED skupin dle Gleasonova sk\u00F3re (GS < 7 a GS > 7) jsme nezaznamenali \u017E\u00E1dn\u00FD rozd\u00EDl. Z\u00E1v\u011Br: SHB je kandid\u00E1tn\u00ED gen n\u00E1chylnosti k vzniku karcinomu prostaty. Jeho exprese je ni\u017E\u0161\u00ED v tk\u00E1ni karcinomu ve srovn\u00E1n\u00ED s tk\u00E1n\u00ED benign\u00ED hyperplazie a kles\u00E1 p\u0159i lok\u00E1ln\u011B pokro\u010Dil\u00FDch stadi\u00EDch."@cs . "C\u00EDl: Karcinom prostaty je nej\u010Dast\u011Bj\u0161\u00ED urologickou onkologickou p\u0159\u00ED\u010Dinou \u00FAmrt\u00ED. Etiologie onemocn\u011Bn\u00ED z\u016Fst\u00E1v\u00E1 nezn\u00E1m\u00E1. Byla identifikov\u00E1na \u0159ada gen\u016F n\u00E1chylnosti ke karcinomu prostaty, u kter\u00FDch byla prok\u00E1z\u00E1na asociace zm\u011Bny genov\u00E9 exprese s v\u00FDskytem karcinomu. Adaptorov\u00FD protein SHB je sou\u010D\u00E1st\u00ED syst\u00E9mu regulace apopt\u00F3zy angiogeneze a bun\u011B\u010Dn\u00E9ho cyklu. P\u0159i jeho zv\u00FD\u0161en\u00E9 expresi byla prok\u00E1z\u00E1na sn\u00ED\u017Een\u00E1 proliferace prostatick\u00FDch n\u00E1dorov\u00FDch bun\u011Bk PC3. C\u00EDlem prezentovan\u00E9 pr\u00E1ce je stanoven\u00ED genov\u00E9 exprese SHB v tk\u00E1ni karcinomu prostaty, jej\u00ED porovn\u00E1n\u00ED s expres\u00ED v tk\u00E1ni benign\u00ED hyperplazie a vyhodnoceni diagnostick\u00E9ho a prognostick\u00E9ho potenci\u00E1lu SHB. Metody: V letech 2008-2010 byla provedena izolace mRNA z tk\u00E1n\u011B karcinomu prostaty u 53 pacient\u016F. Jako kontroln\u00ED skupina byla pou\u017Eita tk\u00E1\u0148 prostaty u 24 pacient\u016F s benign\u00ED hyperplazi\u00ED. Izolace mRNA byla prov\u00E1d\u011Bna u v\u0161ech pacient\u016F identick\u00FDm zp\u016Fsobem pomoc\u00ED soupravy Oligotex Direct mRNA Midi/Maxi. Po RT-PCR byla exprese vybran\u00E9ho vzorku vizualizov\u00E1na pomoc\u00ED elektrofor\u00E9zy Optick\u00E1 hustota byla m\u011B\u0159ena denzitometricky Pro v\u00FDpo\u010Det relativn\u00ED exprese genu byl zvolen provozn\u00ED gen GAD k\u00F3duj\u00EDc\u00ED glyceraldehyd-3-fosf\u00E1tdehydrogen\u00E1zu. Dosa\u017Een\u00E9 v\u00FDsledky byly statisticky vyhodnoceny. V\u00FDsledky: Z\u00EDskan\u00E1 data prok\u00E1zala ni\u017E\u0161\u00ED relativn\u00ED expresi SHB v tk\u00E1n\u00ED karcinomu (p < 0, 001). P\u0159i rozd\u011Blen\u00ED karcinomu na lokalizovan\u00E9 (T2) a lok\u00E1ln\u011B pokro\u010Dil\u00E9 (T3-T4) byl pozorov\u00E1n trend k ni\u017E\u0161\u00ED expresi u lok\u00E1ln\u011B pokro \u010Dil\u00FDch forem, kter\u00FD ale nedos\u00E1hl statistick\u00E9 v\u00FDznamnosti (p < 0,0693). P\u0159i porovn\u00E1n\u00ED skupin dle Gleasonova sk\u00F3re (GS < 7 a GS > 7) jsme nezaznamenali \u017E\u00E1dn\u00FD rozd\u00EDl. Z\u00E1v\u011Br: SHB je kandid\u00E1tn\u00ED gen n\u00E1chylnosti k vzniku karcinomu prostaty. Jeho exprese je ni\u017E\u0161\u00ED v tk\u00E1ni karcinomu ve srovn\u00E1n\u00ED s tk\u00E1n\u00ED benign\u00ED hyperplazie a kles\u00E1 p\u0159i lok\u00E1ln\u011B pokro\u010Dil\u00FDch stadi\u00EDch." . . "\u010Cern\u00FD, M." . "Mare\u0161, Jaroslav" . . "Schmidt, Marek" . "4"^^ . . "\u010Cesk\u00E1 urologie" . "[698FD35D17C7]" . . "170948" . "Stanoven\u00ED exprese SHB v tk\u00E1ni karcinomu prostaty: vyu\u017Eit\u00ED v diagnostice a prognostice" . . "gene expression; prostate cancer; radical prostatectomy; SHB"@en . "9"^^ . "Babjuk, Marek" . "Aim: Among urological malignancies prostate cancer most frequently leads to death. The etiology of this disease remains unknown. Many analyses identified genes associated with increased susceptibility to prostate cancer, where changes in gene expression were associated with prostate cancer. Adaptor protein SHB is involved in apoptosis, angiogenesis and cell cycle regulation systems. A correlation between the expression of SHB, and reduced proliferation of prostate cancer PC3 cells was detected. The aim of this work was to compare SHB expression in prostate cancer to that in benign prostate hyperplasia and to evaluate its diagnostic and prognostic potential. Methods: In 2008-2010, isolation of mRNA from prostate cancer was performed in 53 patients. Twenty four patients with benign prostate hyperplasia were used as a control group. The identical procedure of mRNA isolation using Oligotex Direct mRNA Midi/Maxi was used. RTPCR, expression of specific sample was visualized by electrophoresis. Optical density was measured with densitometry For relative expression calculation, housekeeping gene GAD (glyceralde-hyde-3-phosphate dehydrogenase) was used. Results have been evaluated statistically. Results: Statistically significant decrease in relative expression of SHB in prostate cancer tissue was detected (p < 0.001). In a comparison of patients with localized (T2) and locally advanced tumor, we observed a trend of decreased expression in locally advanced disease which had not achieved statistic significance (p < 0.0693). A comparison between groups detected no differences in the Gleason score (GS < 7 and GS > 7). Conclusion: SHB is a candidate gene for prostate cancer development. Its expression is decreased in prostate cancer compared to benign prostate hyperplasia. Its levels are decreased in locally advanced stages."@en . "RIV/00064203:_____/12:8550" . . . "CZ - \u010Cesk\u00E1 republika" . . "1211-8729" . . "Expression of SHB in prostate cancer tissue: its role in the diagnostics and prognostics"@en . "1" . .